Dr Antonio Pardiñas
Research Associate, Division of Psychological Medicine and Clinical Neurosciences
My research is based on the application of population-genetics methodology to the assessment of the genetic architecture of psychiatric disorders. At the moment, my efforts are directed towards treatment-resistant schizophrenia (TRS). TRS is widely recognised as the most disabling form of schizophrenia, estimated to affect around 1 million individuals in Europe and responsible for a large economic impact in public health. Only one drug to date, clozapine, has been licensed in the UK for the effective treatment of this condition, with no other successful developments occurring in the last four decades. Understanding the biological mechanisms behind such a complex and severe disorder might elucidate potential opportunities for translating genetic knowledge into therapeutic or drug discovery approaches.